-
Product Insights
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) - Global Clinical Trials Review, 2025" provides an overview of Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Sector Analysis
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
This report covers the 7 major markets and provides an Excel-based forecast model for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) market through 2032. GlobalData estimated that drug sales for MASH in 2022 were approximately $802.3 million across the 7MM, with the market size anticipated to grow to approximately $20.3 billion by 2032, at a compound annual growth rate (CAGR) of 38.2%. Major drivers of growth during the forecast period include the anticipated launch of several pipeline agents including those within the...
-
Sector Analysis
Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032
Non-Alcoholic Steatohepatitis (NASH) Report Overview In the 7MM, there were 22,036,613 diagnosed prevalent cases of NASH in 2022. The market is expected to grow at an AGR of more than 2% during 2022-2032. Non-alcoholic steatohepatitis (NASH) is a subcategory of non-alcoholic fatty liver disease (NAFLD), a condition defined by fat accumulation in over 5% of cells in the liver due to causes other than alcohol consumption (Sharma and John, 2022). NASH is considered to be more severe than the non-alcoholic...
-
Product Insights
Non-Alcoholic Steatohepatitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market Report Overview The Non-Alcoholic Steatohepatitis (NASH) clinical trial market research report provides an overview of the NASH clinical trials scenario. The report provides top-line data relating to the clinical trials on NASH. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.